Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.37 |
| ▸ | RELA | Q04206 | 4/20 | 0.37 |
| ▸ | HTR1A | P08908 | 4/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7114678 | 1.00 | KDM4E (0.38) | KDM4EALDH1A1HPGDNFKB1NFKB2 | |
| SCHEMBL6626738 | 0.85 | KDM4E (0.48) | KDM4EALDH1A1HPGDHTR1AHTR1D | |
| SCHEMBL7114723 | 0.85 | KDM4E (0.48) | KDM4EALDH1A1HPGDHTR1AHTR1D | |
| SCHEMBL7313874 | 0.81 | NFKB1 (0.46) | NFKB1NFKB2RELAHTR1AHTR1D | |
| SCHEMBL7115392 | 0.80 | CA2 (0.44) | NFKB1NFKB2RELAHTR1AHTR1D | |
| SCHEMBL7115396 | 0.80 | CA2 (0.44) | NFKB1NFKB2RELAHTR1AHTR1D | |
| SCHEMBL7116097 | 0.78 | NFKB1 (0.57) | NFKB1NFKB2RELA | |
| SCHEMBL7116091 | 0.78 | NFKB1 (0.57) | NFKB1NFKB2RELA | |
| SCHEMBL7857416 | 0.77 | ALDH1A1 (0.35) | KDM4EALDH1A1HPGDNFKB1NFKB2 | |
| SCHEMBL7110632 | 0.75 | CHRM3 (0.40) | ALDH1A1HTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1353670-A2 | USE OF CHROMANES | Bayer Aktiengesellschaft (DE) | 2003-10-22 | — | — | EP | disclosed |
| US-20020177616-A1 | Use of chromans | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-28 | — | — | US | disclosed |
| WO-2002055078-A2 | USE OF CHROMANES FOR TREATING PARKINSON'S DISEASE | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-18 | — | — | WO | disclosed |
| CN-1061043-C | Benzo-iso-thiazolyl substituted amino methyl-benzodipyran | BAYER AG (DE) | 2001-01-24 | — | — | CN | disclosed |
| EP-0749970-B1 | Benzisothiazolyl-substituted aminomethylchroman derivatives | BAYER AG (DE) | 2001-01-17 | — | — | EP | disclosed |
| US-5942529-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-08-24 | — | — | US | disclosed |
| CN-1143079-A | Benzoisothiazolyl-substituted aminomethyl chromans | BAYER AG (DE) | 1997-02-19 | — | — | CN | disclosed |
| EP-0749970-A1 | Benzisothiazolyl-substituted aminomethylchroman derivatives | BAYER AG (DE) | 1996-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177616-A1 | Use of chromans | SNCA, PARK7, COMT | KDM4E 3553/4885ALDH1A1 631/4885HPGD 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.